JP2022550246A - 免疫細胞のインビトロ培養、誘導、活性化、凍結保存方法及びその細胞バンクの作成 - Google Patents
免疫細胞のインビトロ培養、誘導、活性化、凍結保存方法及びその細胞バンクの作成 Download PDFInfo
- Publication number
- JP2022550246A JP2022550246A JP2022507332A JP2022507332A JP2022550246A JP 2022550246 A JP2022550246 A JP 2022550246A JP 2022507332 A JP2022507332 A JP 2022507332A JP 2022507332 A JP2022507332 A JP 2022507332A JP 2022550246 A JP2022550246 A JP 2022550246A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune cells
- medium
- immune
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 108
- 210000004027 cell Anatomy 0.000 title claims abstract description 95
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 48
- 230000006698 induction Effects 0.000 title claims abstract description 26
- 230000004913 activation Effects 0.000 title claims abstract description 23
- 238000000338 in vitro Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000003321 amplification Effects 0.000 claims abstract description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 21
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 12
- 230000006870 function Effects 0.000 claims abstract description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 56
- 239000002609 medium Substances 0.000 claims description 54
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 42
- 210000004698 lymphocyte Anatomy 0.000 claims description 20
- 108010002350 Interleukin-2 Proteins 0.000 claims description 18
- 239000012679 serum free medium Substances 0.000 claims description 18
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 10
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 9
- 239000012595 freezing medium Substances 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 229960005489 paracetamol Drugs 0.000 claims description 5
- 239000000199 parathyroid hormone Substances 0.000 claims description 5
- 229960001319 parathyroid hormone Drugs 0.000 claims description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 5
- 229940016667 resveratrol Drugs 0.000 claims description 5
- 235000021283 resveratrol Nutrition 0.000 claims description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
- 229960002930 sirolimus Drugs 0.000 claims description 5
- 229960003604 testosterone Drugs 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 4
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 4
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 4
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 13
- 230000003833 cell viability Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000012258 culturing Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229930192851 perforin Natural products 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000589884 Treponema pallidum Species 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 101710150350 Albumin-2 Proteins 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 101710150365 Albumin-1 Proteins 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 244000078127 Eleusine coracana Species 0.000 description 1
- 235000013499 Eleusine coracana subsp coracana Nutrition 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000009582 blood typing Methods 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000002079 ragi Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/231—Interleukin-10 (IL-10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/37—Parathyroid hormone [PTH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【選択図】図1
Description
免疫細胞専用の増幅用培地を用いて単核細胞を第1段階の増幅培養を行い、予備増幅免疫細胞を得るステップと、
免疫細胞専用の誘導用培地を用いて、予備増幅免疫細胞を第2段階の誘導・増幅培養を行い、誘導免疫細胞を得るステップと、
免疫細胞専用の活性化用培地を用いて誘導した免疫細胞を第3段階の活性化・増幅培養を行い、機能が活性化された大量の免疫細胞を取得するステップと、
免疫細胞専用の凍結保存液を用いて免疫細胞を凍結保存し、凍結保存した免疫細胞を得るステップと、
ABO/RHタイピングとHLAタイピングに応じて保存することにより、検索可能な免疫細胞情報ファイルを作成し、免疫細胞バンクを構築するステップとを含む。
1.ドナーのスクリーニング
1.1 病院はドナーとインフォームドコンセントに署名しなければならず、1式3通である。ドナー、医療機関は各1通、もう1通は検体とともに実験室に送付する。
取り出した細胞懸濁液10mlを1800rpmで遠心分離し、細胞を回収し、フローサイトメトリー抗体標識を行った。同型対照、単一標準試料、及び染色管を設置し、試料1本当たりの細胞数を約5×105個とし、次に対応する抗体を加えて染色した。4℃で30min放置し、生理食塩水で洗浄した後、装置にかけてリンパ球群中のNK細胞の割合を検出して分析した。
1.14日間培養増幅した実験結果
1.1 14日間培養すると細胞は220倍増幅された。
前記末梢血リンパ球分離液で分離した6×10.07個の末梢血単核細胞を培養系20mlに接種し、細胞はすぐに対数成長段階に入った。14日間培養増幅後、培養系は4Lに拡大し、細胞数は1.3×1010に増幅し、増幅倍数は最大220倍であり、生細胞数は95%以上であり、各培養時間の末梢血単核細胞数と細胞活性の結果は図2に示される。
14日間培養増幅した末梢血単核球では、リンパ球中のNK細胞の割合(CD3-CD56+)は18.15%から97.64%に上昇し、Tリンパ球(CD3+)の割合は71.47%から3.22%に下がり、ヘルパーT細胞(Th、CD3+CD4+)及び細胞傷害性T細胞(Tc、CD3+CD8a+)は全て低下し、Bリンパ球(CD3-CD19+)はほぼ消失し、細胞の均一性が著しく向上し、図1の細胞数を合わせて計算したところ、14日間培養後、NK細胞は1165倍増幅し、14日間培養前後の末梢血単核球中のリンパ球の割合の結果は図3に示され、このうち、NK細胞:CD3-CD56+;T細胞:CD3+;ヘルパーT細胞(Th):CD3+CD4+;細胞傷害性T細胞(Tc細胞):CD3+CD8a+;B細胞:CD3-CD9+であった。
培養後の細胞と細胞懸濁液について、検出プラットフォームに依頼してB型肝炎表面抗原、C型肝炎抗原、ヒト免疫不全ウイルス抗体、梅毒トレポネーマ特異性抗体、マクロファージウイルス及びマイコプラズマ、細菌と内毒素を検出した結果、いずれも陰性であり、これは、このロットの製品が安全であり、培養中に汚染されていないことを示している。
2.1 12日間培養すると細胞は162倍に増幅された。
末梢血リンパ球分離液で分離した6.0×107個の末梢血単核細胞を培養系20mlに接種し、細胞はすぐに対数成長段階に入った。12日間培養後、細胞数は9.7×109に増幅され、増幅倍数は162倍に達し、生細胞数は95%以上であり、実験結果の詳細は図4に示される。
末梢血単核球が12日間増幅された後、リンパ球中のNK細胞の割合(CD3-CD56+)は6日目の21.47%から12日目の93.22%に上昇し、Tリンパ球(CD3+)の割合も3.86%に低下し、ヘルパーT細胞(Th、CD3+CD4+)と細胞傷害性T細胞(Tc、CD3+CD8a+)はいずれも低下し、Bリンパ球(CD3-CD19+)は基本的に消失し、細胞の均一性が著しく向上し、12日間培養前後の末梢血単核細胞中のリンパ球の割合は図5に示される。
培養後の細胞と細胞懸濁液について、検出プラットフォームに依頼してB型肝炎表面抗原、C型肝炎抗原、ヒト免疫不全ウイルス抗体、梅毒トレポネーマ特異性抗体、マクロファージウイルス及びマイコプラズマ、細菌とエンドトキシンを検出した結果、いずれも陰性であり、これは、このロットの製品が安全であり、培養中に汚染されていないことを示している。
ヌードマウス腫瘍誘発実験結果:A群の生理食塩水対照群(腫瘍形成マウス数/群内マウス数、0/5)、B群のRaji細胞対照群(3/5)、C群のK562細胞対照群(4/5)、D群のNK細胞群(0/5)において、2ヶ月観察期間内に生理食塩水0.2mlを皮下注射した群と、3×107個/0.2mlの28日間培養後のNK細胞を皮下注射した群のマウスはいずれも腫瘍形成を認めず、同量のRaji細胞とK562細胞を注射したマウスB群では、それぞれ4/5と5/5匹のマウスに腫瘍形成が認められた。この結果は、28日間培養してもNK細胞が安全で有効であり、腫瘍の形成を引き起こさないことを示している。
凍結保存液1:DMSO 5体積%、アルブミン1体積%、アミノエタノール1体積%、X-VOVO15無血清培地93体積%;
凍結保存液2:DMSO 5体積%、アルブミン2体積%、アミノエタノール2体積%、X-VOVO15無血清培地91体積%;
凍結保存液3:DMSO 5体積%、アルブミン2体積%、X-VOVO15無血清培地93体積%;
凍結保存液4:DMSO 5体積%、アミノエタノール2体積%、X-VOVO15無血清培地93体積%;
凍結保存液5:DMSO 5体積%、X-VOVO15無血清培地95体積%;
凍結保存液6:DMSO 5体積%、自己血漿 10体積%、X-VOVO15無血清培地85体積%;
凍結液は7:DMSO 10体積%、アルブミン2体積%、アミノエタノール2体積%、X-VOVO15無血清培地86体積%。
病院は質問とフォームでドナーの個人情報、過去の治療歴、家族遺伝歴、及び伝染病歴や造血或いは免疫系の異常などの情報を聴取する。病院は、健康診断資料を調べて健康診断情報を得るにはドナーとインフォームドコンセントに署名し、ドナー本人又はその授権者の同意を得らなければならない。ドナーの健康診断情報には、HIV-1/2抗体、HBsAg、抗-HCV、CMV-IgM抗体、ALT、梅毒トレポネーマ抗体が含まれる。個人情報収集表、インフォームドコンセント、検査情報などは番号を付けて密封保存し、検索可能な免疫ドナーファイル情報のデータベースを構築した。
Claims (6)
- 免疫細胞のインビトロ培養、誘導、活性化、凍結保存方法及びその細胞バンクの作成であって、
免疫細胞専用の増幅用培地を用いて単核細胞を第1段階の増幅培養を行い、予備増幅免疫細胞を得るステップであって、前記免疫細胞専用の増幅用培地は、500~2000IU/ml IL-2、500~2000IU/ml IL-10、0.5~1ng/ml IL-1αと1~4ng/ml LIF、0.5~2.5ng/ml EPO、l~4ng/ml KGF、2~5ng/mlテストステロン、1~4μg/ml副甲状腺ホルモン、1~4μg/mlラミニンを添加した無血清リンパ球培地であるステップと、
免疫細胞専用の誘導用培地を用いて、予備増幅免疫細胞を第2段階の誘導・増幅培養を行い、誘導免疫細胞を得るステップと、
免疫細胞専用の活性化用培地を用いて誘導した免疫細胞を第3段階の活性化・増幅培養を行い、機能が活性化された大量の免疫細胞を取得するステップと、
免疫細胞専用の凍結保存液を用いて免疫細胞を凍結保存し、凍結保存した免疫細胞を得るステップと、
ABO/RHタイピングとHLAタイピングに応じて保存することにより、検索可能な免疫細胞情報ファイルを作成し、免疫細胞バンクを構築するステップとを含む、ことを特徴とする方法。 - 前記免疫細胞専用の誘導用培地は、500~2000IU/ml IL-2、500~2000IU/ml IL-10、1~4ng/ml bFGF、1~4ng/ml BMP-4、0.2~0.8μg/ml ラパマイシン、0.2~0.8μg/ml イカリイン、20~80ng/ml トリメチニブ、1~4ng/ml ヒドロコルチゾン、1~4μg/ml ラミニンを添加した無血清リンパ球培地である、ことを特徴とする請求項1に記載の方法。
- 前記免疫細胞専用の活性化用培地は、500~2000IU/ml IL-2、500~2000IU/ml IL-10、1~4ng/ml TGF-β、1~2ng/ml フォルスコリン、20~80ng/ml レスベラトロール、1~4μg/ml アセトアミノフェン、1~4μg/ml ラミニンを添加した無血清リンパ球培地である、ことを特徴とする請求項1に記載の方法。
- 前記免疫細胞専用の凍結保存液は、DMSO 5体積%、アルブミン1~2体積%、アミノエタノール1~2体積%、無血清リンパ球培地91~93体積%を含む、ことを特徴とする請求項1に記載の方法。
- 前記免疫細胞専用の増幅用培地、免疫細胞専用の誘導用培地、免疫細胞専用の活性化用培地、及び免疫細胞専用の凍結保存液において、前記無血清リンパ球培地はX-VOVO15無血清培地又は市販されている他の種類の無血清培地である、ことを特徴とする請求項1~4のいずれか1項に記載の方法。
- 前記免疫細胞はナチュラルキラー細胞である、ことを特徴とする請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010371435.2A CN111454903B (zh) | 2020-05-06 | 2020-05-06 | 免疫细胞体外培养、诱导、激活、冻存方法及其细胞库建立 |
CN202010371435.2 | 2020-05-06 | ||
PCT/CN2020/092287 WO2021223274A1 (zh) | 2020-05-06 | 2020-05-26 | 免疫细胞体外培养、诱导、激活、冻存方法及其细胞库建立 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022550246A true JP2022550246A (ja) | 2022-12-01 |
JP7332787B2 JP7332787B2 (ja) | 2023-08-23 |
Family
ID=71677026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022507332A Active JP7332787B2 (ja) | 2020-05-06 | 2020-05-26 | 免疫細胞のインビトロ培養、誘導、活性化、凍結保存方法及びその細胞バンクの作成 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230051425A1 (ja) |
EP (1) | EP4148123A1 (ja) |
JP (1) | JP7332787B2 (ja) |
KR (1) | KR20230008691A (ja) |
CN (1) | CN111454903B (ja) |
WO (1) | WO2021223274A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114181901B (zh) * | 2021-12-08 | 2024-02-02 | 杭州中赢生物医疗科技有限公司 | 一种免疫细胞的体外诱导扩增和冻存的方法 |
CN114791411A (zh) * | 2022-04-21 | 2022-07-26 | 广州先康达生物科技有限公司 | 评估人体免疫功能的指标组合、试剂盒和方法 |
CN115088708B (zh) * | 2022-07-22 | 2023-05-05 | 厦门锐杰天川生物科技有限公司 | 外周血单个核细胞长期保存方法 |
CN116751745A (zh) * | 2023-08-09 | 2023-09-15 | 北京圣美细胞生命科学工程研究院有限公司 | 一种组合免疫细胞外泌体多肽再生因子及其应用 |
CN117178980B (zh) * | 2023-09-08 | 2024-04-16 | 苏州依科赛生物科技股份有限公司 | 一种免疫细胞低温冻存液及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014030375A (ja) * | 2012-08-02 | 2014-02-20 | Hiroyuki Abe | 単球またはnk細胞を入手する方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2529244C (en) * | 2003-06-12 | 2014-02-18 | The Trustees Of The University Of Pennsylvania | Rapamycin resistant t cells and therapeutic uses thereof |
JP2010501173A (ja) * | 2006-08-23 | 2010-01-21 | バイネックス カンパニー リミテッド | 免疫治療用活性化リンパ球の製造方法 |
WO2016122014A1 (ko) * | 2015-01-27 | 2016-08-04 | 한국생명공학연구원 | 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도 |
CN105524880A (zh) * | 2016-01-27 | 2016-04-27 | 上海润泉生物技术有限公司 | 一种免疫细胞库的构建方法 |
CN106701679B (zh) * | 2016-12-26 | 2018-03-16 | 浙江丹晖生物科技有限公司 | Nk细胞体外扩增培养基组合和培养方法 |
CN106591233B (zh) * | 2016-12-28 | 2018-01-09 | 广州沙艾生物科技有限公司 | 一种免疫细胞的体外诱导扩增和冻存的方法 |
CN106701681B (zh) * | 2016-12-28 | 2018-01-09 | 广州沙艾生物科技有限公司 | 一种免疫细胞的体外诱导扩增、冻存和复苏的方法 |
CN110079499A (zh) * | 2019-05-07 | 2019-08-02 | 青岛大学附属医院 | Nk细胞的分离培养及保存入库的方法 |
-
2020
- 2020-05-06 CN CN202010371435.2A patent/CN111454903B/zh active Active
- 2020-05-26 US US17/634,556 patent/US20230051425A1/en active Pending
- 2020-05-26 JP JP2022507332A patent/JP7332787B2/ja active Active
- 2020-05-26 KR KR1020227004434A patent/KR20230008691A/ko unknown
- 2020-05-26 WO PCT/CN2020/092287 patent/WO2021223274A1/zh unknown
- 2020-05-26 EP EP20934683.2A patent/EP4148123A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014030375A (ja) * | 2012-08-02 | 2014-02-20 | Hiroyuki Abe | 単球またはnk細胞を入手する方法 |
Also Published As
Publication number | Publication date |
---|---|
EP4148123A1 (en) | 2023-03-15 |
US20230051425A1 (en) | 2023-02-16 |
CN111454903A (zh) | 2020-07-28 |
KR20230008691A (ko) | 2023-01-16 |
WO2021223274A1 (zh) | 2021-11-11 |
JP7332787B2 (ja) | 2023-08-23 |
CN111454903B (zh) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7332787B2 (ja) | 免疫細胞のインビトロ培養、誘導、活性化、凍結保存方法及びその細胞バンクの作成 | |
KR101614823B1 (ko) | 조직 복구 및 재생을 위한 세포 증식 방법 및 약제학적 제제 | |
US20190276803A1 (en) | Method of culturing immune cells, kit for thereof, immune cell cultured medium obtained by same method, cosmetic composition and pharmaceutical composition comprising thereof | |
CN106591233B (zh) | 一种免疫细胞的体外诱导扩增和冻存的方法 | |
CN108251365B (zh) | 免疫细胞培养基体系 | |
KR20080018089A (ko) | 면역치료용 활성화 림프구 제조방법 | |
JP7390473B2 (ja) | 間葉系幹細胞のインビトロスクリーニング、活性化、増幅、凍結保存及びその細胞バンクの作成方法 | |
US11944672B2 (en) | Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying Treg cells to produce therapeutic vaccine for treatment of diabetes type 1 | |
Pullarkat et al. | Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells | |
LaVoy et al. | A single bout of dynamic exercise by healthy adults enhances the generation of monocyte-derived-dendritic cells | |
CN104039333B (zh) | 移植物抗宿主疾病的治疗或预防方法 | |
US20210238549A1 (en) | Use of memory lymphocyte population in liver cancer treatment | |
CN106754704A (zh) | 免疫细胞体外诱导扩增的方法 | |
WO2023216799A1 (zh) | 一种人nkt细胞系及其应用 | |
TW200404002A (en) | Treatment method achieved by using the lymphocytes derived from HLA matching donor-originating activated lymphocytes, formula having the lymphocytes as a main constituent thereof; method and preparation kit for manufacturing the formula | |
WO2021167094A1 (ja) | 末梢血原料の採取/凍結融解工程における単球純化法 | |
CN110747167B (zh) | 一种半合子bak细胞的制备方法及其应用 | |
CN111154721B (zh) | Nk细胞扩增方法 | |
CN108148805A (zh) | 一种人Tscm细胞及其制备方法和应用 | |
Arroyo et al. | Adoptive immunotherapy with antiviral T cells: materials and methods | |
CN110656084B (zh) | Bak细胞及其制备试剂盒和制备方法 | |
CN113512529B (zh) | 特异性抗病毒过继免疫细胞ab的制备方法 | |
RU2372936C1 (ru) | Способ получения аутологичной вакцины для лечения туберкулеза | |
Tan et al. | Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia. | |
AL-Hamdani et al. | Effect of Trichothececns toxin on stem cells isolated from Umbilical cord blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230720 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230801 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230810 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7332787 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |